Trial Profile
Open-label Follow-up Study of the VIPES Study to Evaluate Long-term Efficacy and Safety of the Viaskin Peanut
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Peanut allergy immunotherapy (Primary)
- Indications Peanut hypersensitivity
- Focus Therapeutic Use
- Acronyms OLFUS-VIPES
- Sponsors DBV Technologies
- 04 Jul 2022 Last checked against ClinicalTrials.gov record.
- 29 May 2018 Results presented in the DBV Technologies media release.
- 29 May 2018 Data from this trial were presented at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting, according to a DBV Technologies media release.